EU103
1 abstract
Abstract
Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer.Org: Eutilex Co., Ltd., Samsung Medical Center, Sungkyunkwan University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,